Why Ozempic shortages keep happening
Global Ozempic supply has been under pressure since 2022 as off-label demand for weight loss exploded beyond Novo Nordisk's original manufacturing forecasts (which assumed Ozempic would be used exclusively for type 2 diabetes). Manufacturing capacity is being scaled, but injection-pen production is technically complex and slow to expand.
Australia faces additional pressure becaus. It is a smaller market, when global supply tightens, larger markets (US, EU) typically receive prioritised allocation. This is a commercial reality of multinational pharmaceutical supply chains, not specific to Australia.
The TGA monitors supply via its Medicine Shortages Register. Pharmacists and prescribers also receive notifications from Novo Nordisk Australia about anticipated supply changes.
If your pharmacy is out, the practical playbook
Step 1: Try multiple pharmacies
Supply varies by pharmacy chain, location, and ordering patterns. Independent pharmacies sometimes have stock when chains don’t. Smaller suburban pharmacies often have better availability than busy inner-city ones. Ring around, your prescription is valid at any Australian pharmacy.
Step 2: Ask about strength substitution
If your maintenance dose is 1.0mg but only 0.5mg pens are available, your prescriber may amend the script to use two 0.5mg doses per week (administered as one weekly injection of 0.5mg + another mid-week, only with prescriber approval). This is non-standard so requires clinical sign-off.
Alternatively, your prescriber may temporarily reduce your dose to whatever is available, accepting a brief reduction in therapeutic effect. Discuss with them rather than self-adjusting.
Step 3: Telehealth providers often have stock
Major Australian telehealth weight-loss platforms (Juniper, Pilot, Mosh, Eucalyptus) often have better supply visibility and prioritised allocation. Bundled telehealth pricing typically also undercuts retail pharmacy. Switching to a telehealth model during supply pressure can be both cheaper and more reliable.
Step 4: Switch to Wegovy or Mounjaro
If Ozempic supply is genuinely unavailable for weeks, consider switching:
| Switching to | Cost impact | Switching process |
|---|---|---|
| Wegovy | $31.60 PBS → $420-530 private (~14x) | Same molecule. Continue equivalent dose. Same brand (Novo Nordisk). |
| Mounjaro | $31.60 PBS → $450-580 private (~15x) | Different molecule. 7-day washout. Restart at 2.5mg. Re-titrate. |
| Saxenda | $31.60 PBS → $340-420 private (~11x) | Different molecule (liraglutide). Daily injection. Largely superseded by weekly options. |
For type 2 diabetes patients specifically
If you’re on PBS-subsidised Ozempic for T2D and supply is unavailable, switching options are clinically suitable but financially painful. Discuss with your prescriber:
- Wait it out. Most shortages resolve within weeks. Adequate metformin or other PBS-subsidised T2D medications may bridge the gap.
- Switch to another PBS-subsidised T2D medication. Other GLP-1 agonists (e.g., dulaglutide / Trulicity) may also be PBS-eligible under different Authority criteria.
- Pay privately for Wegovy or Mounjaro short-term. Often unsustainable long-term but viable as a 4-8 week bridge.
What to AVOID during shortages
- Compounded semaglutide. Not TGA-assessed. Quality and dose accuracy concerns. AHPRA has issued cautions.
- Personal importation from overseas. Not legal for ongoing chronic therapy. Cold-chain integrity, quality, and TGA compliance not assured.
- "Pharmacy" sales via social media or online marketplaces. Counterfeit Ozempic has been seized by TGA in 2024-2025. Only buy through registered Australian pharmacies.
- Stockpiling beyond your prescription. Worsens shortages for other patients. Pharmacy dispensing rules limit it anyway.
- Self-adjusting dose to "make supply last." Don’t reduce frequency or split pens without prescriber sign-off, affects therapeutic efficacy and side effect profile.